Ipilimumab, a humanized monoclonal anti-CTLA-4 antibody, plus nivolumab, a PD-1 inhibitor, demonstrated an ORR of 0% in low- and intermediate-grade carcinoid tumors. The gene discussed is CTLA4; the disease is carcinoid tumor.